Mersana Therapeutics (MRSN) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Agriculture Biodegradable Climate Environment Environmental Extreme Weather Materials Nature Offset Package Packaging Pandemic Raw Materials Regenerative Scarcity Toxic Waste Water Wind Access Affordability African American Asian Benefits Black California Consumer Privacy Act Collective Bargaining Community Culture Customer Cyber Cyber Security Data Privacy Data Security Death Demographic Disability Diversity Drug Pricing Employee Engagement Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Latinx LGBTQ Minority Pay for Performance Perquisites Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workers Workforce Workplace Safety Action Plan Anti-corruption Antitrust Assessment Assurance Attorneys General Audit Bonus Bribery Classified Classified Board Clawback Commitment Corporate Governance Corporate Purpose Corruption Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Perquisite Plaintiff Pledging Purpose Quality Standard R&D Recoup Reputation Reputational Reputational Risk Research and Development Responsibility Responsible Special Meeting Strategy Supermajority Sustainability Sustainable Targets Tax Tenure Transparency Transparent Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On June 9, 2022, the Company held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following four proposals: (1) to elect three Class II directors to serve until the Company’s 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified (“Proposal 1”), (2) to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 (“Proposal 2”), (3) to approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement on Schedule 14A filed by the Company with the U.S. Securities and Exchange Commission on April 29, 2022 (“Proposal 3”) and (4) to approve an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of Common Stock from 175,000,000 to 350,000,000 (“Proposal 4”). The final results of the voting on each proposal are set forth below.

Proposal 1 - Election of Directors

The Company’s stockholders elected the three persons listed below as Class II directors, each to serve until the Company’s 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows:

Nominees
Allene M. Diaz	53,799,152	20,146,322	9,826,119
Andrew A. F. Hack, M.D., Ph.D.	52,483,663	21,461,811	9,826,119
Kristen Hege, M.D.	46,368,816	27,576,658	9,826,119

Proposal 2 – Ratification of Selection of Independent Registered Public Accounting Firm

The Company’s stockholders approved Proposal 2. The votes cast were as follows:

For				Against				Abstain
	83,355,355				407,164				9,074

Proposal 3 – Advisory Vote on Executive Compensation

The Company’s stockholders did not approve Proposal 3. The votes cast were as follows:

For				Against				Abstain				Broker Non-Votes
	32,599,465				40,822,166				523,843				9,826,119

Proposal 4 – Approval of Amendment to Certificate of Amendment to Certificate of Incorporate to Increase Authorized Shares of Common Stock

The Company’s stockholders approved Proposal 4. The votes cast were as follows:

For				Against				Abstain
	72,173,407				11,550,718				47,468

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.